Navigation Links
The Complexities, Cost of Midwest Biotech Drug Development

CHICAGO In trying to explain the complexities of the biotech industry to investors, academics and start-up biotech companies, most people now understand that it is a long, painstaking and expensive process. What they don't understand is why.

A brief primer in the drug discovery and development process shows us the following pathway:

Logical questions to the above inc......

Full article >>> ese type of diseases by granting orphan drug designation. This designation provides a company with both fast-track review as well as seven years market exclusivity from the time the drug is actually approved by the FDA (independent of the drugs patent status).

Another situation with the FDA exists for drugs for life-threatening disea......

Full article >>> nt to 80 percent of the cost and about 60 percent of the time to develop a drug is in the clinical phase of development (testing in humans), it is critical to ask this question up front before even starting clinical trials.

It has been said that it costs up to $800 to $900 million for Big Pharma to develop a successful drug. That is a higher amount than you are citing. Why?

Full article >>> y.

Happy Thanksgiving! See you next week!


Full article >>>
'"/> By Michael Rosen 11/24/03

Related biology technology :

1. Midwest life science stocks kept sizzling in Q2
2. Midwest life science stocks sizzle in a tepid first quarter
3. A Midwest passage to India, Part II
4. Midwest offers non-stop flight to North Carolina research park
5. A Midwest life-science odyssey comes full circle
6. Midwest hotter for healthcare investments
7. A Midwest small-cap, life-science surprise package
8. 2006: A mixed blessing for Midwest life science companies
9. Midwest gaining stature in nanotech research
10. Midwest colleges strong contenders for NIH funds
11. Japan on the rebound: Implications for Midwest
Post Your Comments:

(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):